参考文献/References:
[1] Yancy CW,Jessup M,Bozkurt B,et al. 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure:a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America[J]. Circulation,2017,136(6):e137-e161.
[2] Bozkurt B,Coats AJS,Tsutsui H,et al. Universal definition and classification of heart failure:a report of the Heart Failure Society of America,Heart Failure Association of the European Society of Cardiology,Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure:Endorsed by the Canadian Heart Failure Society,Heart Failure Association of India,Cardiac Society of Australia and New Zealand,and Chinese Heart Failure Association[J]. Eur J Heart Fail,2021,23(3):352-380.
[3] Lewis KS,Butler J,Bauersachs J,et al. The three-decade long journey in heart failure drug development[J]. Handb Exp Pharmacol,2017,243:1-14.
[4] Redfield MM,Chen HH,Borlaug BA,et al. Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction:a randomized clinical trial[J]. JAMA,2013,309(12):1268-1277.
[5] Schmidt HH,Schmidt PM,Stasch JP. NO- and haem-independent soluble guanylate cyclase activators[J]. Handb Exp Pharmacol,2009,191:309-339.
[6] Murad F. Nitric oxide signaling:would you believe that a simple free radical could be a second messenger,autacoid,paracrine substance,neurotransmitter,and hormone?[J]. Recent Prog Horm Res,1998,53:43-59.
[7] Ignarro LJ,Buga GM,Wood KS,et al. Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide[J]. Proc Natl Acad Sci U S A,1987,84(24):9265-9269.
[8] Ignarro LJ,Byrns RE,Wood KS. Endothelium-dependent modulation of cGMP levels and intrinsic smooth muscle tone in isolated bovine intrapulmonary artery and vein[J]. Circ Res,1987,60(1):82-92.
[9] Fleming I,Busse R. NO:the primary EDRF[J]. J Mol Cell Cardiol,1999,31(1):5-14.
[10] Beavo JA,Brunton LL. Cyclic nucleotide research—Still expanding after half a century[J]. Nat Rev Mol Cell Biol,2002,3(9):710-718.
[11] Evgenov OV,Pacher P,Schmidt PM,et al. NO-independent stimulators and activators of soluble guanylate cyclase:discovery and therapeutic potential[J]. Nat Rev Drug Discov,2006,5(9):755-768.
[12] Boerrigter G,Lapp H,Burnett JC. Modulation of cGMP in heart failure:a new therapeutic paradigm[J]. Handb Exp Pharmacol,2009,191:485-506.
[13] Hofmann F,Feil R,Kleppisch T,et al. Function of cGMP-dependent protein kinases as revealed by gene deletion[J]. Physiol Rev,2006,86(1):1-23.
[14] Lam CSP,Voors AA,de Boer RA,et al. Heart failure with preserved ejection fraction:from mechanisms to therapies[J]. Eur Heart J,2018,39(30):2780-2792.
[15] van Heerebeek L,Hamdani N,Falc?o-Pires I,et al. Low myocardial protein kinase G activity in heart failure with preserved ejection fraction[J]. Circulation,2012,126(7):830-839.
[16] Kemp-Harper BK,Velagic A,Paolocci N,et al. Cardiovascular therapeutic potential of the redox siblings,nitric oxide (NO?) and nitroxyl (HNO),in the setting of reactive oxygen species dysregulation[J]. Handb Exp Pharmacol,2021,264:311-337.
[17] Wilck N,Markó L,Balogh A,et al. Nitric oxide-sensitive guanylyl cyclase stimulation improves experimental heart failure with preserved ejection fraction[J]. JCI Insight,2018,3(4):e96006.
[18] Zuchi C,Tritto I,Carluccio E,et al. Role of endothelial dysfunction in heart failure[J]. Heart Fail Rev,2020,25(1):21-30.
[19] Masuyama H,Tsuruda T,Sekita Y,et al. Pressure-independent effects of pharmacological stimulation of soluble guanylate cyclase on fibrosis in pressure-overloaded rat heart[J]. Hypertens Res,2009,32(7):597-603.
[20] Kolijn D,Kovács ?,Herwig M,et al. Enhanced cardiomyocyte function in hypertensive rats with diastolic dysfunction and human heart failure patients after acute treatment with soluble guanylyl cyclase (sGC) activator[J]. Front Physiol,2020,11:345.
[21] Zern EK,Ho JE,Panah LG,et al. Exercise intolerance in heart failure with preserved ejection fraction:arterial stiffness and aabnormal left ventricular hemodynamic responses during exercise[J]. J Card Fail,2021,27(6):625-634.
[22] Abudiab MM,Redfield MM,Melenovsky V,et al. Cardiac output response to exercise in relation to metabolic demand in heart failure with preserved ejection fraction[J]. Eur J Heart Fail,2013,15(7):776-785.
[23] Borlaug BA,Olson TP,Lam CS,et al. Global cardiovascular reserve dysfunction in heart failure with preserved ejection fraction[J]. J Am Coll Cardiol,2010,56(11):845-854.
[24] Farrokhi E,Shafei MN,Khajavirad A,et al. Role of the nitrergic system of the cuneiform nucleus in cardiovascular responses in urethane-anesthetized male rats[J]. Iran J Med Sci,2017,42(5):473-480.
[25] Shapiro BP,McGoon MD,Redfield MM. Unexplained pulmonary hypertension in elderly patients[J]. Chest,2007,131(1):94-100.
[26] Adir Y,Humbert M,Sitbon O,et al. Out-of-proportion pulmonary hypertension and heart failure with preserved ejection fraction[J]. Respiration,2013,85(6):471-477.
[27] Stasch JP,Hobbs AJ. NO-independent,haem-dependent soluble guanylate cyclase stimulators[J]. Handb Exp Pharmacol,2009,191:277-308.
[28] Armstrong PW,Roessig L,Patel MJ,et al. A multicenter,randomized,double-blind,placebo-controlled trial of the efficacy?and safety of the oral soluble guanylate cyclase stimulator:the VICTORIA trial[J]. JACC Heart Fail,2018,6(2):96-104.
[29] Pieske B,Butler J,Filippatos G,et al. Rationale and design of the SOluble guanylate Cyclase stimulatoR in heArT failurE Studies (SOCRATES)[J]. Eur J Heart Fail,2014,16(9):1026-1038.
[30] Gheorghiade M,Greene S J,Butler J,et al. Effect of vericiguat,a soluble guanylate cyclase stimulator,on natriuretic peptide levels in patients with worsening chronic heart failure and reduced ejection fraction:the SOCRATES-REDUCED randomized trial[J]. JAMA,2015,314(21):2251-2262.
[31] Pieske B,Maggioni AP,Lam CSP,et al. Vericiguat in patients with worsening chronic heart failure and preserved ejection fraction:results of the SOluble guanylate Cyclase stimulatoR in heArT failurE patientS with PRESERVED EF (SOCRATES-PRESERVED) study[J]. Eur Heart J,2017,38(15):1119-1127.
[32] Filippatos G,Maggioni AP,Lam CSP,et al. Patient-reported outcomes in the SOluble guanylate Cyclase stimulatoR in heArT failurE patientS with PRESERVED ejection fraction (SOCRATES-PRESERVED) study[J]. Eur J Heart Fail,2017,19(6):782-791.
[33] Bonderman D,Pretsch I,Steringer-Mascherbauer R,et al. Acute hemodynamic effects of riociguat in patients with pulmonary hypertension associated with diastolic heart failure (DILATE-1):a randomized,double-blind,placebo-controlled,single-dose study[J]. Chest,2014,146(5):1274-1285.
[34] Armstrong PW,Lam CSP,Anstrom KJ,et al. Effect of vericiguat vs placebo on quality of life in patients with heart failure and preserved ejection fraction:the VITALITY-HFpEF randomized clinical trial[J]. JAMA,2020,324(15):1512-1521.
[35] Udelson JE,Lewis GD,Shah SJ,et al. Effect of praliciguat on peak rate of oxygen consumption in patients with heart failure with preserved ejection fraction:the CAPACITY HFpEF randomized clinical trial[J]. JAMA,2020,324(15):1522-1531.
相似文献/References:
[1]丁娟,刘地川.心力衰竭与线粒体功能障碍的研究进展[J].心血管病学进展,2016,(1):84.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.022]
DING Juan,LIU Dichuan.Research Progress of Heart Failure and Mitochondrial Dysfunction[J].Advances in Cardiovascular Diseases,2016,(2):84.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.022]
[2]罗秀林,综述,张烁,等.肾动脉去交感神经术治疗心力衰竭——希望还是炒作[J].心血管病学进展,2016,(3):268.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.013]
LUO Xiulin,ZHANG Shuo.Renal Sympathetic Denervation for Heart Failure—Hopes or Hypes[J].Advances in Cardiovascular Diseases,2016,(2):268.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.013]
[3]查凤艳,综述,覃数,等.心源性恶病质发病机制的研究进展[J].心血管病学进展,2016,(3):282.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.017]
ZHA Fengyan,QIN Shu.Advances in Pathogenesis of Cardiac Cachexia[J].Advances in Cardiovascular Diseases,2016,(2):282.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.017]
[4]李慧,综述,齐国先,等.老年射血分数保留的心功能不全研究进展[J].心血管病学进展,2016,(4):354.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.007]
LI Hui,QI Guoxian.Research Progress of Heart Failure with Preserved Ejection Fraction in Elderly People[J].Advances in Cardiovascular Diseases,2016,(2):354.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.007]
[5]亢玉,综述,张庆,等.二尖瓣瓣叶在功能性二尖瓣反流发生机制中的角色[J].心血管病学进展,2016,(4):376.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.013]
KANG Yu,ZHANG Qing.Role of Mitral Leaflets in Pathogenesis of Functional Mitral Regurgitation[J].Advances in Cardiovascular Diseases,2016,(2):376.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.013]
[6]史秀莉,张庆,喻鹏铭.心力衰竭患者运动训练方式及其疗效的研究进展[J].心血管病学进展,2015,(5):535.[doi:10.3969/j.issn.1004-3934.2015.05.003]
SHI Xiuli,ZHANG Qing,YU Pengming.Exercise Training Modalities and Their Treatment Effects on
Patients with Heart Failure[J].Advances in Cardiovascular Diseases,2015,(2):535.[doi:10.3969/j.issn.1004-3934.2015.05.003]
[7]熊卓超,陈康玉,严激.无创血流动力学评价在心力衰竭中的应用进展[J].心血管病学进展,2019,(6):923.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.021]
XIONG Zhuochao,CHEN Kangyu,YAN Ji.Application Progress of Noninvasive Hemodynamic Evaluation in Heart Failure[J].Advances in Cardiovascular Diseases,2019,(2):923.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.021]
[8]高薇 陈伟.铁过载性心肌病[J].心血管病学进展,2019,(5):680.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.006]
GAO WeiCHEN Wei.Iron Overload Cardiomyopathy[J].Advances in Cardiovascular Diseases,2019,(2):680.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.006]
[9]何燕 刘育.C型利钠肽与心力衰竭[J].心血管病学进展,2019,(5):745.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.020]
HE Yan,LIU Yu.C-type Natriuretic Peptide and Heart Failure[J].Advances in Cardiovascular Diseases,2019,(2):745.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.020]
[10]吴彤 高东来.心房颤动合并心力衰竭的射频消融治疗[J].心血管病学进展,2019,(5):757.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.023]
WU TongGAO Donglai.Catheter Ablation of Atrial Fibrillation in Patients with Heart Failure[J].Advances in Cardiovascular Diseases,2019,(2):757.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.023]
[11]菲尔凯提·玉山江李昊穆叶赛·尼加提.射血分数保留性心力衰竭合并糖尿病的研究进展[J].心血管病学进展,2020,(4):373.[doi:10.16806/j.cnki.issn.1004-3934.2020.04.011]
FEIERKAITI·Yushanjiang,LIHao,MUYESAI.Nijiati.Heart Failure With Preserved Ejection Fraction and Diabetes Mellitus[J].Advances in Cardiovascular Diseases,2020,(2):373.[doi:10.16806/j.cnki.issn.1004-3934.2020.04.011]
[12]石玉姣 熊双 刘春秋 杨晨光 董国菊 刘剑刚.射血分数保留性心力衰竭潜在的分子机制及治疗靶点[J].心血管病学进展,2022,(5):423.[doi:10.16806/j.cnki.issn.1004-3934.2022.05.010]
SHI Yujiao,XIONG Shuang,LIU Chunqiu,et al.Potential Molecular Mechanisms and Therapeutic Target in Heart Failure with Preserved Ejection Fraction[J].Advances in Cardiovascular Diseases,2022,(2):423.[doi:10.16806/j.cnki.issn.1004-3934.2022.05.010]